Clinical Trials on Metastatic Head and Neck Squamous Cell Carcinoma in New Zealand

Total 3467 results

BioAtla, Inc.

Recruiting

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma of the Head and Neck

United States
Incyte Biosciences International Sàrl

Withdrawn

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Malignancies | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Novartis Pharmaceuticals

Terminated

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

France, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
Rain Oncology Inc

Terminated

Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have | Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC

Active, not recruiting

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and Neck

United States
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

United States, Canada, France, Spain, Belgium, Czechia, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Australia, Germany, Georgia, Israel
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals

Recruiting

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer | Neck Cancer | Head Cancer Neck

United States
Sanofi
Groupe Oncologie Radiotherapie Tete et Cou

Completed

TRACE: Tirapazamine-Radiation And Cisplatin Evaluation (TRACE)

Head and Neck Squamous Cell Carcinoma

United States, France, Canada, Poland, Germany, Spain, Switzerland, Singapore, Taiwan, Argentina, Hungary, Italy, Chile, Hong Kong, South Africa, Australia, New Zealand
Icahn School of Medicine at Mount Sinai

Recruiting

Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer | Recurrent Head and Neck Squamous Cell Cancer | Metastatic Head and Neck Squamous Cell Cancer

United States
Krzysztof Misiukiewicz
Regeneron Pharmaceuticals

Recruiting

Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Head and Neck Squamous Cell Carcinoma

United States
AstraZeneca
MedImmune LLC

Active, not recruiting

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Spain, United States, Belgium, Germany, United Kingdom, Italy
Memorial Sloan Kettering Cancer Center
Celgene Corporation; National Comprehensive Cancer Network

Completed

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

HEAD & NECK Cancer

United States
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
All India Institute of Medical Sciences, New Delhi

Unknown

Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell Carcinoma

HEAD AND NECK CANCER

India
Pfizer
EMD Serono; Astellas Pharma Inc; Nektar Therapeutics

Terminated

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)

Spain, United States, Poland, Belgium
Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States
Queensland Health
Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma (DESQUAMATE)

Head and Neck Cancer | Cutaneous Squamous Cell Carcinoma of the Head and Neck

Australia
Exicure, Inc.

Terminated

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Merkel Cell Carcinoma | Advanced or Metastatic Cutaneous Squamous Cell Carcinoma | Advanced or Metastatic Melanoma | Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

United States
Andrew Sikora
Advaxis, Inc.

Completed

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
Trans Tasman Radiation Oncology Group

Active, not recruiting

Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPVOropharynx)

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Australia, New Zealand
PDS Biotechnology Corp.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (VERSATILE002)

HPV Positive Oropharyngeal Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Neoplasms, Head and Neck

United States, Puerto Rico, Ireland, United Kingdom
Yale University

Completed

Window Trial 5-aza in HNSCC, T-tare

Head and Neck Squamous Cell Carcinoma

United States
Dynavax Technologies Corporation
Merck Sharp & Dohme LLC

Terminated

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Metastatic Melanoma | Head Neck Cancer

United States, Germany, New Zealand, Australia
Memorial Sloan Kettering Cancer Center

Completed

Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
Icahn School of Medicine at Mount Sinai

Withdrawn

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

Human Papillomavirus (HPV) | Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
New Mexico Cancer Care Alliance
Lovelace Respiratory Research Institute

Active, not recruiting

Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC

Head and Neck Squamous Cell Carcinoma

United States
Yale University
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab in HNSCC With Residual Disease After Radiation

Head and Neck Squamous Cell Carcinoma

United States
Beth Israel Medical Center

Completed

Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck (Unilateral)

Squamous Cell Carcinoma of the Head and Neck

United States
Krzysztof Misiukiewicz
Sanofi; Icahn School of Medicine at Mount Sinai

Completed

Cabazitaxel - PF Induction Chemotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

United States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
Roswell Park Cancer Institute

Withdrawn

Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients

Head and Neck Squamous Cell Carcinoma

United States
Roswell Park Cancer Institute

Completed

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

United States
ALX Oncology Inc.
Merck Sharp & Dohme LLC

Recruiting

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Korea, Republic of, United Kingdom, Spain, Belgium, Singapore, Canada, Netherlands, Australia
Bristol-Myers Squibb

Completed

A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe

Squamous Cell Carcinoma of the Head and Neck

United States
Ascendis Pharma Oncology Division A/S

Recruiting

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor | Locally Advanced Solid Tumor | Neoadjuvant Melanoma | Head and Neck Squamous Cell Carcinoma HNSCC | HPV-associated Cancers | Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)

United States, Australia, Spain, Netherlands, Korea, Republic of, Taiwan
Presage Biosciences
AstraZeneca

Recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
Cascadian Therapeutics Inc.

Completed

Phase 1 and 2 Study of PX-866 and Cetuximab

Incurable Metastatic Colorectal Carcinoma | Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

United States, Canada
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Locally Advanced Head and Neck Squamous Cell Carcinoma

Spain, United States, Italy, Korea, Republic of, United Kingdom, Vietnam, France, Japan, Brazil, India, Thailand, Germany, Canada, Turkey, Malaysia, Taiwan, Belgium, Austria, Hungary
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic... and other conditions

United States
Roswell Park Cancer Institute

Recruiting

Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial

Head and Neck Squamous Cell Carcinoma

United States
Icahn School of Medicine at Mount Sinai

Recruiting

The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)

HPV-positive Oropharyngeal Squamous Cell Carcinoma

United States
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
Celldex Therapeutics

Terminated

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Advanced Head and Neck Squamous Cell Carcinoma

United States
Presage Biosciences
Takeda

Completed

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

Head and Neck Squamous Cell Carcinoma

United States

Clinical Trials on Metastatic Head and Neck Squamous Cell Carcinoma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations